

---

## MEDIA FACT SHEET

### Premark Pharma – Quick Facts

- Privately-owned development-stage pharmaceutical company
- Based in Basel, Switzerland; Established in 2018
- Focused on the development and commercialisation of topical treatments for inflammatory diseases of the skin, eye, mucosae and mucocutaneous surfaces
- Lead asset is PMP2207 for blepharitis; Phase 3 studies are in development
- Management team includes experts in ophthalmic clinical practice, drug development and strategic marketing
- The lead investor is a consortium of US-based ophthalmologists

#### PPM2207 and Blepharitis

PMP2207 is novel ocular formulation of an established anti-inflammatory medicine being developed for blepharitis. Phase 3 studies are in development. If approved, PMP2207 would be the first prescription treatment for blepharitis.

Blepharitis is a chronic inflammatory condition of the eyelids, eyelid margins and ocular surface, affecting more than 10 million people in the United States<sup>1,2</sup>.

#### Management team:

- Ian Vessey, Managing Director: 30 years experience in the pharmaceutical industry, including 15 years working in global strategic marketing roles, mostly operating at the clinical-commercial interface. This includes four years as Head of Early Phase Marketing for the Novartis Ophthalmics Business Unit, which exposed him to all the major eye markets, including blepharitis and dry eye.
- Friedrich K. Mayer Head of Development: 45 years experience in the pharmaceutical industry. He built and led multidisciplinary global project teams, taking six new molecular entities (NMEs) from research through registration to life cycle management.

#### Advisors:

- Prof. Dr. Thomas Reinhard, Medical Director, Eye Center, University Hospital Freiburg, Germany
- Prof. Dr. Daniel Böhringer, Head of Clinical Trials Group, Eye Center, University Hospital Freiburg, Germany
- William Stewart MD, Medical Director PRN Pharmaceutical Research Network, LLC and Director PRN PharmaFarm, LLC

1. Lemp MA, Nichols KK; Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. *Ocular Surface*. 2009; 7(Suppl 2): S1–14.
2. William WC, Stewart JA, Nelson LA; Blepharitis: New Treatment Survey. Data on File, 2019

#### Contact:

Ian Vessey, Founder & Managing Director  
Telephone: +41 796 19 37 44; Email: [ivessey@premarkpharma.com](mailto:ivessey@premarkpharma.com)